Skip to Main Content

Paper Details

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
Eur Urol
3
2023
-regulatory elements, AR, AR cistrome, Androgen, Androgen Receptor, GG1, GG1 tumors, Grade Group 1 Prostate Cancers, PATIENT, androgen, androgen receptor, androgen receptor protein, benign prostate tissue, cancer, cancers, chromatin, grade tumors, higher-grade cancers, low, low-grade GG1 prostate cancers, low-grade cancers, low-grade tumors, noncancerous, noncancerous benign tissue, primary, prostate cancer disease, prostate cancers, target genes, tumor, tumor-defining cis, tumors
Author NameAffiliation
Tesa M SeversonOncode Institute, The Netherlands Cancer Institute
Mark M PomerantzDana-Farber Cancer Institute, Harvard Medical School
Mark M PomerantzDana-Farber Cancer Institute, Harvard Medical School
Matthew L FreedmanThe Eli and Edythe L. Broad Institute, The Netherlands Cancer Institute
Matthew L FreedmanThe Eli and Edythe L. Broad Institute, The Netherlands Cancer Institute
Andries M BergmanThe Netherlands Cancer Institute
Wilbert ZwartOncode Institute, The Netherlands Cancer Institute, The Netherlands Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology
  • 1 - 7

Datasets

Release 1.2